Alpha 1-antitrypsin Pi-types in 965 COPD patients
- PMID:3485034
- DOI: 10.1378/chest.89.3.370
Alpha 1-antitrypsin Pi-types in 965 COPD patients
Abstract
To study further the role of intermediate alpha 1-antitrypsin (AAT) deficiency in chronic obstructive pulmonary disease (COPD), AAT Pi-types and serum-trypsin-inhibitory-capacity (STIC) were measured in 965 patients with COPD. Heterozygosity of the Z variant was the major cause of intermediate AAT deficiency (primarily the MZ phenotype), accounting for 8.0 percent of the patients compared to 2.9 percent of control subjects (p less than .0005). ZZ homozygosity was detected in 1.9 percent of the patients, compared to 0.04 percent of control studies performed by others (none was present in our own control group of 1,380 subjects). The mean age for MS or MZ patients did not differ from that of the COPD patients as a whole, whereas the ZZ homozygotes were younger (55.9 +/- 9.8 vs 65.3 +/- 7.5 years). These results resemble those of a previous study in 66 male veterans with pulmonary emphysema suggesting that the MZ phenotype, or intermediate AAT deficiency in general, probably does predispose to the development of COPD. However, the prevalence of AAT deficiency in COPD patients is small (approximately 10 percent). The number with an MS phenotype was not increased in this group of COPD patients.
Similar articles
- The prevalence of alpha-antitrypsin heterozygotes (Pi MZ) in patients with obstructive pulmonary disease.Shigeoka JW, Hall WJ, Hyde RW, Schwartz RH, Mudholkar GS, Speers DM, Lin CC.Shigeoka JW, et al.Am Rev Respir Dis. 1976 Dec;114(6):1077-84. doi: 10.1164/arrd.1976.114.6.1077.Am Rev Respir Dis. 1976.PMID:1087539
- Liver Phenotypes of European Adults Heterozygous or Homozygous for Pi∗Z Variant of AAT (Pi∗MZ vs Pi∗ZZ genotype) and Noncarriers.Schneider CV, Hamesch K, Gross A, Mandorfer M, Moeller LS, Pereira V, Pons M, Kuca P, Reichert MC, Benini F, Burbaum B, Voss J, Gutberlet M, Woditsch V, Lindhauer C, Fromme M, Kümpers J, Bewersdorf L, Schaefer B, Eslam M, Bals R, Janciauskiene S, Carvão J, Neureiter D, Zhou B, Wöran K, Bantel H, Geier A, Dirrichs T, Stickel F, Teumer A, Verbeek J, Nevens F, Govaere O, Krawczyk M, Roskams T, Haybaeck J, Lurje G, Chorostowska-Wynimko J, Genesca J, Reiberger T, Lammert F, Krag A, George J, Anstee QM, Trauner M, Datz C, Gaisa NT, Denk H, Trautwein C, Aigner E, Strnad P; European Alpha-1 Liver Study Group.Schneider CV, et al.Gastroenterology. 2020 Aug;159(2):534-548.e11. doi: 10.1053/j.gastro.2020.04.058. Epub 2020 May 4.Gastroenterology. 2020.PMID:32376409
- Heterozygosity in the Pi-system as a pathogenetic cofactor in chronic obstructive pulmonary disease (COPD).Bartmann K, Fooke-Achterrath M, Koch G, Nagy I, Schütz I, Weis E, Zierski M.Bartmann K, et al.Eur J Respir Dis. 1985 Apr;66(4):284-96.Eur J Respir Dis. 1985.PMID:3874784
- Alpha-1 antitrypsin (AAT) augmentation therapy in individuals with the PI*MZ genotype: a pro/con debate on a working hypothesis.Barjaktarevic I, Miravitlles M.Barjaktarevic I, et al.BMC Pulm Med. 2021 Mar 23;21(1):99. doi: 10.1186/s12890-021-01466-x.BMC Pulm Med. 2021.PMID:33757485Free PMC article.Review.
- Alpha1-antitrypsin deficiency. 2: genetic aspects of alpha(1)-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk.DeMeo DL, Silverman EK.DeMeo DL, et al.Thorax. 2004 Mar;59(3):259-64. doi: 10.1136/thx.2003.006502.Thorax. 2004.PMID:14985567Free PMC article.Review.
Cited by
- Changes in prevalence of chronic obstructive pulmonary disease and asthma in the US population and associated risk factors.Halldin CN, Doney BC, Hnizdo E.Halldin CN, et al.Chron Respir Dis. 2015 Feb;12(1):47-60. doi: 10.1177/1479972314562409. Epub 2014 Dec 24.Chron Respir Dis. 2015.PMID:25540134Free PMC article.
- Development of predictive models for airflow obstruction in alpha-1-antitrypsin deficiency.Castaldi PJ, DeMeo DL, Kent DM, Campbell EJ, Barker AF, Brantly ML, Eden E, McElvaney NG, Rennard SI, Stocks JM, Stoller JK, Strange C, Turino G, Sandhaus RA, Griffith JL, Silverman EK.Castaldi PJ, et al.Am J Epidemiol. 2009 Oct 15;170(8):1005-13. doi: 10.1093/aje/kwp216. Epub 2009 Sep 2.Am J Epidemiol. 2009.PMID:19726494Free PMC article.
- α₁-Antitrypsin protease inhibitor MZ heterozygosity is associated with airflow obstruction in two large cohorts.Sørheim IC, Bakke P, Gulsvik A, Pillai SG, Johannessen A, Gaarder PI, Campbell EJ, Agustí A, Calverley PM, Donner CF, Make BJ, Rennard SI, Vestbo J, Wouters EF, Paré PD, Levy RD, Coxson HO, Lomas DA, Hersh CP, Silverman EK.Sørheim IC, et al.Chest. 2010 Nov;138(5):1125-32. doi: 10.1378/chest.10-0746. Epub 2010 Jul 1.Chest. 2010.PMID:20595457Free PMC article.
- The Aryl Hydrocarbon Receptor and the Maintenance of Lung Health.Guerrina N, Traboulsi H, Eidelman DH, Baglole CJ.Guerrina N, et al.Int J Mol Sci. 2018 Dec 5;19(12):3882. doi: 10.3390/ijms19123882.Int J Mol Sci. 2018.PMID:30563036Free PMC article.Review.
- A functional mutation in the terminal exon of elastin in severe, early-onset chronic obstructive pulmonary disease.Kelleher CM, Silverman EK, Broekelmann T, Litonjua AA, Hernandez M, Sylvia JS, Stoler J, Reilly JJ, Chapman HA, Speizer FE, Weiss ST, Mecham RP, Raby BA.Kelleher CM, et al.Am J Respir Cell Mol Biol. 2005 Oct;33(4):355-62. doi: 10.1165/rcmb.2005-0206OC. Epub 2005 Aug 4.Am J Respir Cell Mol Biol. 2005.PMID:16081882Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous